Achieve Life Sciences, Inc. (ACHV) Stock Price & Analysis
Achieve Life Sciences, Inc. (ACHV) rose 2.19% to USD 5.6 as of June 10, 2026 at 03:43 UTC, according to Nexqual real-time market data.
ACHV last closed at USD 5.48; the session ranged USD 5.36–5.74 on volume of 1,188,219 shares. Market capitalization is $574.89M, with a 52-week range of USD 2–6.15 (NCM). Source: Nexqual, June 10, 2026 at 03:43 UTC.
Key Statistics (as of June 10, 2026 at 03:43 UTC)
| Price | USD 5.6 |
|---|---|
| Change | ▲ 2.19% (up) |
| Previous Close | USD 5.48 |
| Open | USD 5.59 |
| Day Range | USD 5.36 – 5.74 |
| 52-Week Range | USD 2 – 6.15 |
| Volume | 1,188,219 shares |
| Market Cap | $574.89M |
| Exchange | NCM |
Technical Analysis (ACHV)
Nexqual's technical model rates ACHV "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.24 (neutral) |
| vs SMA50 | Above (USD 4.46) |
| MACD | 0.21 (positive) |
Analyst Ratings (ACHV)
Wall Street analysts rate ACHV "None" based on 9 analysts, with a mean price target of USD 13.11 (range USD 9–21), per Nexqual as of June 10, 2026 at 03:43 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 13.11 |
| High Target | USD 21 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (ACHV)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.28 ▼ miss |
| 2025-09-30 | USD -0.28 vs est -0.26 ▼ miss |
| 2025-06-30 | USD -0.37 vs est -0.35 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
Financials & Fundamentals (ACHV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -496.15% |
| Debt / Equity | 140.03 |
| Current Ratio | 2.63 |
| Total Cash | $29.27M |
| Total Debt | $14.95M |
| Free Cash Flow | $-26.95M |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
Financial Health Score (ACHV)
Nexqual rates Achieve Life Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $29M cash vs $15M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$45M |
| Efficiency | Critical — ROE -496%, ROA -108.4% |
Ownership (ACHV)
| Insider Ownership | +0.93% |
|---|---|
| Institutional Ownership | +60.97% |
| Shares Outstanding | 102.66M |
| Float | 87.25M |
| Short % of Float | +7.52% |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
Leadership (ACHV)
Achieve Life Sciences, Inc. is led by Andrew D. Goldberg (age 43), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:43 UTC.
| CEO, President & Director | Andrew D. Goldberg (age 43) |
|---|---|
| Chief Financial Officer | Mark K. Oki (age 56) |
| Senior Vice President of Commercial | Mark Zappia |
| Vice President of Strategic Communications & Stakeholder Relations | Nicole P. Jones |
Major Backers & Investors (ACHV)
Notable institutional backers of Achieve Life Sciences, Inc. include Franklin Resources, Inc., Propel Bio Management, LLC, Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND, according to Nexqual as of June 10, 2026 at 03:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Franklin Resources, Inc. | 4.26% |
| Propel Bio Management, LLC | 3.69% |
| Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | 1.53% |
| Simplify Asset Management, Inc. | 1.15% |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 1.15% |
| Millennium Management | 1.05% |
| Marshall Wace LLP | 0.99% |
| LPL Financial LLC | 0.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.25% |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
From Achieve Life Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
- The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
- It has license and supply agreements with Sopharma AD and University of Bristol.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AKTX | Akari Therapeutics Plc | USD 15 | ▼ 0.46% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
| DARE | Dare Bioscience, Inc. | USD 1.92 | ▲ 2.13% |
| PRPO | Precipio, Inc. | USD 23.32 | ▼ 0.72% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:43 UTC. This page is informational and not investment advice.